Plandai Biotechnology Inc (PLPL)

[stervc]

Truenorth2016, huge PLPL/PuriBlood "compare and contrast"...

I think all should first read your PLPL posts below:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169247150
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169302255

Then I think all should go back and read the recently released PLPL PR below:
https://www.otcmarkets.com/stock/PLPL/news/Plandai-Biotechnology-In-Non-Binding-Letter-of-Intent-to-Acquire-Rights-to-Puribloods-Leukocyte-Reduction-Blood-Filtrati?id=358235

Now I think people should understand that when you are acquiring all rights to the licensing and distribution of something like this for 30 years as per the PR, it is huge because you acquire the revenue flow of how the money will be made while not acquiring all or any of the expenses that are associated with the acquisition.

With the video that you posted, there is a compare and contrast slide with PuriBlood being compared to some very good companies to where it looks like PuriBlood is better with having a 99.99% removal ratio of Leukocytes from the blood:
https://video.medicalexpo.com/video_me/videos/video-71808.mp4
(Got to the 1:06 timestamp.)

Those companies to where it looks like the PuriBlood's process of removal of Leukocytes is better than are...

* Fresenius Kabi which generated 37.25 Billion EUR (or $38.3 Billion) for the year
* Haemonetics which generated $988 Million for the year
*  Fenwal which generates $297.7 Million for the year

I think the closure of PuriBlood will be absolutely huge for PLPL. I think all should keep in mind that anything with the past management won't be important because PLPL will be having a new management team with a new direction to move forward as per the PR so investors should focus on the future and not the past:

https://www.otcmarkets.com/stock/PLPL/news/Plandai-Biotechnology-In-Non-Binding-Letter-of-Intent-to-Acquire-Rights-to-Puribloods-Leukocyte-Reduction-Blood-Filtrati?id=358235
Under the terms of the proposed agreement, the current holder of the worldwide rights, exclusive of Taiwan, Jessie Chiang, via entities she controls, will license to Plandai the exclusive rights to the Puriblood technology for North, Central, and South America for a period of 30 years. Upon closing of the proposed transaction, Ms. Chiang will acquire the controlling interest in the Company and will become the Company's Director, President, and Chief Executive Officer. Ms. Chiang will then appoint new members to the board of directors and will move to establish a board of advisors consisting of leading industry, finance, and business experts.

Also important to note from the PR, is that the product has already been approved by the FDA as can be confirmed below of which it appears that they have a manufacturer for their product approved by the FDA too (INNOVATIVE MEDICAL MANUFACTURING CO.):

https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/TextSearch.cfm
(Search the word... Puriblood)
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/TextResults.cfm


https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=618717&lpcd=KSR


https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=618825&lpcd=KSR

v/r
Sterling